Hypera (HYPE3) Panoramica del titolo
Hypera S.A. opera come azienda farmaceutica in Brasile. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 4/6 |
Premi
Analisi del rischio
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Hypera S.A.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | R$22.56 |
| Massimo di 52 settimane | R$28.87 |
| Minimo di 52 settimane | R$20.66 |
| Beta | 0 |
| Variazione di 1 mese | 0.089% |
| Variazione a 3 mesi | -6.39% |
| Variazione di 1 anno | -10.41% |
| Variazione a 3 anni | -45.55% |
| Variazione a 5 anni | -38.02% |
| Variazione dall'IPO | 170.18% |
Notizie e aggiornamenti recenti
Articolo di analisi • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...
Aggiornamento della narrazione • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Recent updates
Articolo di analisi • May 07
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...Aggiornamento della narrazione • Feb 05
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Aggiornamento della narrazione • Jan 20
HYPE3: Slight Index Exit And Firm P/E Outlook Will Support Upside
Analysts have nudged their price target for Hypera slightly lower to reflect small adjustments in fair value, discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a modest trim of about R$0.15 per share. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how some index and benchmark aware investors treat the stock (Key Developments).Aggiornamento della narrazione • Jan 05
HYPE3: Future P/E Multiple Expansion Will Support Further Upside Potential
Analysts have slightly increased their price target on Hypera to reflect updated fair value estimates and adjustments to revenue growth, profit margin expectations, and future P/E assumptions. What's in the News Hypera S.A. is scheduled to hold a board meeting on Dec 11, 2025, which may address governance, capital allocation, or operational planning (company event filing).Articolo di analisi • Dec 28
Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento della narrazione • Dec 15
HYPE3: Future P E Expansion Will Support Further Upside Potential
Analysts have slightly raised their price target on Hypera to $30.24 from $30.14, citing modestly stronger revenue growth expectations that more than offset a small downward revision in projected profit margins and a higher implied future P/E multiple. Valuation Changes Fair Value Estimate has risen slightly from R$30.14 to R$30.24 per share, reflecting a modestly higher intrinsic valuation.Articolo di analisi • Dec 01
What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Hypera...Aggiornamento della narrazione • Dec 01
HYPE3: Future P/E Expansion Signals Continued Upside Potential
Analysts have increased their price target for Hypera from $29.59 to $30.14, citing revised estimates that reflect a slightly higher discount rate as well as updated projections for revenue growth and profit margin. Valuation Changes Fair Value: Increased slightly from R$29.59 to R$30.14 per share.Articolo di analisi • Nov 05
Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Hypera S.A.'s ( BVMF:HYPE3 ) stock showed strength, with investors undeterred by its weak earnings report. We think...Articolo di analisi • Sep 05
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Aug 10
Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Hypera S.A. ( BVMF:HYPE3 ), who've watched their investment drop 10% to R$23.19 in the week...Articolo di analisi • Jun 15
The Price Is Right For Hypera S.A. (BVMF:HYPE3)
With a price-to-earnings (or "P/E") ratio of 21.7x Hypera S.A. ( BVMF:HYPE3 ) may be sending very bearish signals at...Articolo di analisi • Apr 23
Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Mar 27
Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hypera S.A.'s ( BVMF:HYPE3 ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Nuova narrazione • Mar 23
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.Articolo di analisi • Feb 24
Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
With a median price-to-earnings (or "P/E") ratio of close to 8x in Brazil, you could be forgiven for feeling...Articolo di analisi • Nov 21
More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
To the annoyance of some shareholders, Hypera S.A. ( BVMF:HYPE3 ) shares are down a considerable 27% in the last month...Articolo di analisi • Nov 14
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Oct 03
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
There wouldn't be many who think Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10x is worth a...Articolo di analisi • Jul 13
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 20
Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10.9x right now seems...Articolo di analisi • Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Hypera S.A. ( BVMF:HYPE3 ) had a good week, as its shares rose 3.3% to close at R$34.10 following the...Articolo di analisi • Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 12.7x right now seems...Articolo di analisi • Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...Articolo di analisi • Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Articolo di analisi • Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 13x might make it look like a sell right now...Rendimenti per gli azionisti
| HYPE3 | BR Pharmaceuticals | BR Mercato | |
|---|---|---|---|
| 7D | -1.1% | 2.9% | -0.7% |
| 1Y | -10.4% | 22.9% | 13.7% |
Ritorno vs Industria: HYPE3 ha avuto una performance inferiore rispetto al BR Pharmaceuticals che ha registrato un rendimento 22.9 % nell'ultimo anno.
Rendimento vs Mercato: HYPE3 ha avuto una performance inferiore al mercato BR che ha registrato un rendimento 13.7 % nell'ultimo anno.
Volatilità dei prezzi
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in BR Market | 8.2% |
| 10% least volatile stocks in BR Market | 1.9% |
Prezzo delle azioni stabile: HYPE3 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato BR.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di HYPE3 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1999 | 10,564 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. opera come azienda farmaceutica in Brasile. Offre prodotti da prescrizione con i marchi Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, Luna, Lydian, Macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, Oximax, Peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma e Velunid. L'azienda fornisce anche prodotti per la protezione solare e l'idratazione della pelle con i marchi Mantecorp Skincare; prodotti simili con i marchi Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum e Torsilax; e farmaci da banco a marchio Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil e Neosaldina, oltre a farmaci simili e generici a marchio Neo Química.
Hypera S.A. Riepilogo dei fondamenti
| HYPE3 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | R$15.87b |
| Utili (TTM) | R$1.20b |
| Ricavi(TTM) | R$7.70b |
13.3x
Rapporto P/E2.1x
Rapporto P/SHYPE3 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| HYPE3 Conto economico (TTM) | |
|---|---|
| Ricavi | R$7.70b |
| Costo del fatturato | R$3.15b |
| Profitto lordo | R$4.55b |
| Altre spese | R$3.35b |
| Utili | R$1.20b |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Aug 06, 2026
| Utile per azione (EPS) | 1.70 |
| Margine lordo | 59.04% |
| Margine di profitto netto | 15.53% |
| Rapporto debito/patrimonio netto | 74.6% |
Come si è comportato HYPE3 nel lungo periodo?
Vedi performance storica e confrontoDividendi
5.2%
Rendimento attuale del dividendo62%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/25 13:32 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Hypera S.A. è coperta da 22 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |